Disease · MONDO_0005335

colorectal neoplasm

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. colorectal neoplasm. Diseases, record MONDO_0005335. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005335

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: colorectal neoplasm; Open Targets
Open Targets ID: MONDO_0005335; Open Targets
Other names: colorectal tumor, colorectal tumour, colorectum neoplasm, colorectum neoplasm (disease), colorectum tumor, colorectum tumour, large bowel neoplasm, large bowel tumor, large bowel tumour, large intestinal neoplasm, large intestine neoplasm, large intestine tumor, large intestine tumour, neoplasm of colorectum, neoplasm of large bowel, neoplasm of the large bowel, tumor of colorectum, tumor of large bowel, tumor of the large bowel, tumour of colorectum, tumour of large bowel, tumour of the large bowel; Open Targets
MeSH: D015179; MeSH
NCI Thesaurus: C2956; NCI Thesaurus
Highest stage of its drugs: Approval, for 16 of its 26 drugs, from DailyMed, EMA Human Drugs and FDA; Open Targets

Drugs26

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Source
BEVACIZUMAB	CHEMBL1201583	Antibody	Approval	EMA Human Drugs	11	Drugs and targets
CAPECITABINE	CHEMBL1773	Small molecule	Approval	EMA Human Drugs	6	Drugs and targets
FRUQUINTINIB	CHEMBL4303214	Small molecule	Approval	EMA Human Drugs and FDA	2	Drugs and targets
AFLIBERCEPT	CHEMBL1742982	Protein	Approval	EMA Human Drugs	1	Drugs and targets
ARCITUMOMAB	CHEMBL2108253	Antibody	Approval	EMA Human Drugs, at withdrawal	1	Drugs and targets
CELECOXIB	CHEMBL118	Small molecule	Approval	DailyMed	1	Drugs and targets
CETUXIMAB	CHEMBL1201577	Antibody	Approval	EMA Human Drugs	1	Drugs and targets
ENCORAFENIB	CHEMBL3301612	Small molecule	Approval	EMA Human Drugs	1	Drugs and targets
IPILIMUMAB	CHEMBL1789844	Antibody	Approval	EMA Human Drugs	1	Drugs and targets
METHYLENE BLUE ANHYDROUS	CHEMBL405110	Small molecule	Approval	EMA Human Drugs	1	Drugs and targets

1 to 10 of 26

See all 26 drugs

Targets41

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
BRAF	Serine/threonine-protein kinase B-raf	2	Serine/threonine-protein kinase B-raf inhibitor	Approval	https://conductscience.org/library/genes/673	Drugs and targets
EGFR	Epidermal growth factor receptor	2	Epidermal growth factor receptor erbB1 inhibitor	Approval	https://conductscience.org/library/genes/1956	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	2	Vascular endothelial growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/2321	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	2	Vascular endothelial growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/2324	Drugs and targets
KDR	Vascular endothelial growth factor receptor	2	Vascular endothelial growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/3791	Drugs and targets
TYMS	Thymidylate synthase	2	Thymidylate synthase inhibitor	Approval	https://conductscience.org/library/genes/7298	Drugs and targets
VEGFA	Vascular endothelial growth factor A, long form	2	Vascular endothelial growth factor A inhibitor	Approval	https://conductscience.org/library/genes/7422	Drugs and targets
ABL1	Tyrosine-protein kinase ABL1	1	Tyrosine-protein kinase ABL inhibitor	Approval	https://conductscience.org/library/genes/25	Drugs and targets
CEACAM5	Cell adhesion molecule CEACAM5	1	Carcinoembryonic antigen-related cell adhesion molecule 5 binding agent	Approval	https://conductscience.org/library/genes/1048	Drugs and targets
CSF2	Granulocyte-macrophage colony-stimulating factor	1	Granulocyte-macrophage colony-stimulating factor vaccine antigen	Phase 2	https://conductscience.org/library/genes/1437	Drugs and targets

1 to 10 of 41

See all 41 targets

Trials5

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01985763	Genistein in Treatment of Metastatic Colorectal Cancer	Phase 1/2	13	2019-05-10	Colon Cancer, Rectal Cancer, Colorectal Cancer	GENISTEIN	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT02791334	A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors	Phase 1	164		Solid Tumor, Microsatellite Instability-High (MSI-H) Solid Tumors, Cutaneous Melanoma, Pancreatic Cancer, Breast Cancer (HR+HER2-)	LODAPOLIMAB, LY-3321367	Open Targets' reading of its record	ClinicalTrials.gov
NCT00236249	Safety and Efficacy Study of Intravenous Lidocaine After Colorectal Surgery: LIDOREHAB	Phase 3	110		Colorectal Neoplasms	LIDOCAINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT05913674	Technical Feasibility of Modified Early Post-Operative Intraperitoneal Chemotherapy (mEPIC)	Phase 2	25		Peritoneal Carcinomatosis, Appendiceal Neoplasms, Colorectal Cancer Metastatic	FLUOROURACIL	Open Targets' reading of its record	ClinicalTrials.gov
NCT01329809	Neoadjuvant Recombinant Vaccinia Virus for Metastatic Colorectal Cancer With Liver Resection	Phase 2	2		Colorectal Carcinoma	PEXASTIMOGENE DEVACIREPVEC	Open Targets' reading of its record	ClinicalTrials.gov

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Genistein vs Genistein and Chemotherapy: deaths from any cause	0 of 13	0 of 13	26	NCT01985763	Trial comparisons
Genistein vs Genistein and Chemotherapy: serious adverse events	0 of 13	0 of 13	26	NCT01985763	Trial comparisons

Papers from its trials3

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
34465599	DERIVED	1	PubMed
33229456	DERIVED	1	PubMed
31203390	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005335

GET https://conductscience.org/api/diseases/v1/MONDO_0005335/drugs?page=2

API reference For AI assistants